London, UK – 5th May 2026 — Curaleaf Laboratories today announced a significant milestone in the advancement of medical cannabis treatments in the United Kingdom, becoming the first licensed manufacturer in the country to develop and produce medical cannabis suppositories and pessaries.
This pioneering step expands the range of clinically appropriate delivery formats available for specialist prescribers to provide their patients, addressing unmet needs for individuals who may not benefit from traditional administration methods.
Following requests from doctors listed on the specialist register, products have been developed in accordance with UK regulatory standards and Good Manufacturing Practice (GMP) guidelines, ensuring consistent quality, safety, and reliability. Curaleaf Laboratories has worked closely with clinicians and researchers throughout the development process to ensure the formulations meet rigorous medical and pharmaceutical standards.
“Patient-centric innovation is at the core of everything we do,” said Richard Hodgson, Managing Director at Curaleaf Laboratories. “By introducing these new dosage forms, we are broadening access to medical cannabis in a way that reflects the diverse clinical needs of patients across the UK. This is a meaningful step forward in normalising and advancing cannabis-based medicines within modern healthcare.”
This innovation aligns with the growing body of international research exploring alternative cannabinoid delivery systems and underscores Curaleaf Laboratories’ commitment to advancing evidence-based cannabis therapies in order to increase acceptance of this treatment in the UK.
UK-manufactured medical cannabis suppositories and pessaries have been manufactured and will be available on prescription by clinicians listed on the UK Specialist Register from today.
If you are an interested healthcare professional seeking information on prescribing or ordering, please contact us.
Patients seeking information from their dispensing pharmacy may visit Curaleaf Pharmacy if applicable. Treatment decisions should be made in consultation with a qualified healthcare professional.
Disclaimer: This press release includes information about cannabis-based products for medicinal use. These products are available in the UK only via prescription from a specialist doctor. This announcement is not intended to promote prescription-only medicines to the public. Treatment decisions should be made by a qualified healthcare professional.
About Curaleaf Laboratories
Curaleaf Laboratories is a UK-leading expert in the manufacture and distribution of EU-GMP medical cannabis. With a state-of-the-art MHRA-approved medical cannabis manufacturing facility and a comprehensive quality management system, Curaleaf Laboratories is meeting the growing needs of healthcare professionals and patients for a consistent range of medical cannabis manufactured to EU-GMP standards, with varying novel dosage forms and levels of cannabinoid content.
Part of the Curaleaf International group since 2019, Curaleaf Laboratories has evolved from an established specials medicines manufacturer with over a decade of expertise in unlicensed medicines. With that experience, Curaleaf Laboratories is widening access to clinics and pharmacies all across the UK, with a focus on innovation and collaboration, while leading the market as a trusted manufacturer, distributor and partner.